Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPC-009
- Development stage
- Preclinical
- Lead developer
- Tetra Pharm Technologies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TPC-009 is an investigational cannabinoid-based drug candidate being developed by Tetra Pharm Technologies for the treatment of schizophrenia. The drug utilizes the company's proprietary Tetra Pharm Carrier (TPC) technology, a specialized drug delivery system designed to enhance the bioavailability and therapeutic efficacy of lipophilic cannabinoid molecules. TPC-009 is intended to modulate the endocannabinoid system to address the complex pathophysiology of schizophrenia, potentially targeting the neurotransmitter imbalances associated with the disorder. As of early 2024, the program is in the discovery to pre-clinical stage of development.
Beyond the preview
Go deeper on TPC-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPC-009.